Darusentan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Darusentan
Darusentan.svg
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Metabolism Hepatic
Biological half-life 12.5 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
ECHA InfoCard 100.126.841
Chemical and physical data
Formula C22H22N2O6
Molar mass 410.42 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences,[1] under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.

In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.[2]

In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study.

See also[edit]

References[edit]